JP2019537576A5 - - Google Patents

Download PDF

Info

Publication number
JP2019537576A5
JP2019537576A5 JP2019522377A JP2019522377A JP2019537576A5 JP 2019537576 A5 JP2019537576 A5 JP 2019537576A5 JP 2019522377 A JP2019522377 A JP 2019522377A JP 2019522377 A JP2019522377 A JP 2019522377A JP 2019537576 A5 JP2019537576 A5 JP 2019537576A5
Authority
JP
Japan
Prior art keywords
aav
particle according
aav particle
disease
particles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019522377A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019537576A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/059986 external-priority patent/WO2018085688A1/en
Publication of JP2019537576A publication Critical patent/JP2019537576A/ja
Publication of JP2019537576A5 publication Critical patent/JP2019537576A5/ja
Priority to JP2022169285A priority Critical patent/JP2023002721A/ja
Pending legal-status Critical Current

Links

JP2019522377A 2016-11-04 2017-11-03 神経変性疾患を処置するための遺伝子移入用組成物、遺伝子導入法、及び遺伝子導入の使用 Pending JP2019537576A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022169285A JP2023002721A (ja) 2016-11-04 2022-10-21 神経変性疾患を処置するための遺伝子移入用組成物、遺伝子導入法、及び遺伝子導入の使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662418033P 2016-11-04 2016-11-04
US62/418,033 2016-11-04
PCT/US2017/059986 WO2018085688A1 (en) 2016-11-04 2017-11-03 Gene transfer compositions, methods and uses for treating neurodegenerative diseases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022169285A Division JP2023002721A (ja) 2016-11-04 2022-10-21 神経変性疾患を処置するための遺伝子移入用組成物、遺伝子導入法、及び遺伝子導入の使用

Publications (2)

Publication Number Publication Date
JP2019537576A JP2019537576A (ja) 2019-12-26
JP2019537576A5 true JP2019537576A5 (enExample) 2020-12-03

Family

ID=62075988

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019522377A Pending JP2019537576A (ja) 2016-11-04 2017-11-03 神経変性疾患を処置するための遺伝子移入用組成物、遺伝子導入法、及び遺伝子導入の使用
JP2022169285A Pending JP2023002721A (ja) 2016-11-04 2022-10-21 神経変性疾患を処置するための遺伝子移入用組成物、遺伝子導入法、及び遺伝子導入の使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022169285A Pending JP2023002721A (ja) 2016-11-04 2022-10-21 神経変性疾患を処置するための遺伝子移入用組成物、遺伝子導入法、及び遺伝子導入の使用

Country Status (9)

Country Link
US (1) US20190269797A1 (enExample)
EP (1) EP3534892A4 (enExample)
JP (2) JP2019537576A (enExample)
CN (1) CN110198712A (enExample)
AU (1) AU2017355502B2 (enExample)
BR (1) BR112019009074A2 (enExample)
CA (1) CA3041548A1 (enExample)
MX (1) MX2019005266A (enExample)
WO (1) WO2018085688A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9818239B2 (en) 2015-08-20 2017-11-14 Zendrive, Inc. Method for smartphone-based accident detection
EP3635009B1 (en) 2017-06-07 2026-02-25 Regeneron Pharmaceuticals, Inc. Compositions and methods for internalizing enzymes
US10559196B2 (en) 2017-10-20 2020-02-11 Zendrive, Inc. Method and system for vehicular-related communications
IL276464B2 (en) 2018-02-07 2026-01-01 Regeneron Pharma Methods and compositions for administering therapeutic protein
MA52626A (fr) 2018-05-17 2021-03-24 Regeneron Pharma Anticorps anti-cd63, conjugués et leurs utilisations
CN113966399A (zh) 2018-09-26 2022-01-21 加州理工学院 用于靶向基因疗法的腺相关病毒组合物
SG11202104295UA (en) * 2018-11-14 2021-06-29 Regenxbio Inc Gene therapy for neuronal ceroid lipofuscinoses
CA3127889A1 (en) * 2019-02-01 2020-08-06 Spark Therapeutics, Inc. Aav vector treatment methods for late infantile neuronal ceroid lipofuscinosis type 2
WO2021113475A1 (en) 2019-12-03 2021-06-10 Zendrive, Inc. Method and system for risk determination of a route
CN115244181B (zh) * 2020-03-11 2025-08-08 上海信致医药科技有限公司 阿司匹林化合物在增加核酸表达中的新型用途
WO2025231406A1 (en) * 2024-05-02 2025-11-06 The Children's Hospital Of Philadelphia Methods to increase transduction of ependyma cells in brain

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070003518A1 (en) * 2002-04-19 2007-01-04 Atkinson Mark A Raav vector-based compositions and methods for the prevention and treatment of mammalian diseases
US20040258666A1 (en) * 2003-05-01 2004-12-23 Passini Marco A. Gene therapy for neurometabolic disorders
WO2005071085A1 (ja) * 2004-01-22 2005-08-04 Dnavec Research Inc. ウイルスベクターの製造方法
EP1986661B1 (en) * 2006-02-08 2018-08-29 Genzyme Corporation Gene therapy for niemann-pick disease type a
PT3252161T (pt) * 2007-06-06 2022-02-01 Genzyme Corp Terapia genética para doenças do armazenamento lisossomal
CA2832151C (en) * 2011-03-31 2021-06-15 University Of Iowa Research Foundation Methods and compositions for treating brain diseases
CA3209883A1 (en) * 2013-07-22 2015-01-29 The Children's Hospital Of Philadelphia Variant aav and compositions, methods and uses for gene transfer to cells, organs and tissues
BR112016001592A2 (pt) * 2013-07-26 2017-11-28 Univ Iowa Res Found métodos e composições para o tratamento de doenças cerebrais
CN105745326A (zh) * 2013-10-24 2016-07-06 优尼科Ip有限公司 用于基因治疗神经疾病的aav-5假型载体
ES2874704T3 (es) * 2013-11-20 2021-11-05 Univ Iowa Res Found Procedimiento para monitorizar la eficacia de un tratamiento de la enfermedad de Alzheimer con una isoforma de ApoE
CN108601771B (zh) * 2015-10-23 2023-02-21 衣阿华大学研究基金会 使用基因疗法以推迟疾病发生和发展同时提供认知保护来治疗神经变性疾病的方法
IL316926A (en) * 2017-05-11 2025-01-01 Univ Pennsylvania Gene therapy for neuronal ceroid lipofuscinosis

Similar Documents

Publication Publication Date Title
JP2019537576A5 (enExample)
Liu et al. Crossing the blood-brain barrier with AAV vectors
JP2019511570A5 (enExample)
US20250360225A1 (en) Adeno-associated virus vector delivery of a fragment of micro-dystrophin to treat muscular dystrophy
JP2016503405A5 (enExample)
JP2009526067A5 (enExample)
JP2020519629A5 (enExample)
RU2017115477A (ru) Полинуклеотиды aadc для лечения болезни паркинсона
JP2008540445A5 (enExample)
JP2018506585A5 (enExample)
IL273776B2 (en) Gene therapies for lysosomal disorders
JPWO2020106916A5 (enExample)
IL263009B2 (en) Optimal clni genes and expression cassettes and their use
FI3373980T3 (fi) Menetelmiä lihasdystrofian hoitamiseksi
Ortolano et al. Present and future of adeno associated virus based gene therapy approaches
JPWO2020006458A5 (enExample)
JPWO2019204593A5 (enExample)
US20230277687A1 (en) Viral particles for use in treating tauopathies such as alzheimer's diseases by gene therapy
RU2019117062A (ru) Композиции, способы и применения переноса генов для лечения нейродегенеративных заболеваний
JPWO2019226832A5 (enExample)
JP2023059858A5 (enExample)
JPWO2022034130A5 (enExample)
JPWO2019200286A5 (enExample)
JPWO2020237130A5 (enExample)
JPWO2023086966A5 (enExample)